These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

595 related items for PubMed ID: 25845927

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Extended-spectrum β-lactamase-producing Enterobacteriaceae, national study of antimicrobial treatment for pediatric urinary tract infection.
    Lagree M, Bontemps S, Dessein R, Angoulvant F, Madhi F, Martinot A, Cohen R, Dubos F, GPIPGroupe de pathologie infectieuse pédiatrique (Paediatric Infectious Disease Group), France..
    Med Mal Infect; 2018 May; 48(3):193-201. PubMed ID: 29449049
    [Abstract] [Full Text] [Related]

  • 3. Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
    Ofer-Friedman H, Shefler C, Sharma S, Tirosh A, Tal-Jasper R, Kandipalli D, Sharma S, Bathina P, Kaplansky T, Maskit M, Azouri T, Lazarovitch T, Zaidenstein R, Kaye KS, Marchaim D.
    Infect Control Hosp Epidemiol; 2015 Aug; 36(8):981-5. PubMed ID: 25990361
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Activity of beta-lactam beta-lactamase inhibitor combinations against extended spectrum Beta-lactamase producing Enterobacteriaceae in urinary isolates.
    Afridi FI, Farooqi BJ.
    J Coll Physicians Surg Pak; 2012 Jun; 22(6):358-62. PubMed ID: 22630093
    [Abstract] [Full Text] [Related]

  • 7. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.
    Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ, Avdic E, Cosgrove SE, Antibacterial Resistance Leadership Group.
    Clin Infect Dis; 2015 May 01; 60(9):1319-25. PubMed ID: 25586681
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS, Loeb M, Brooks AA.
    Postgrad Med; 2017 Mar 01; 129(2):242-258. PubMed ID: 27712137
    [Abstract] [Full Text] [Related]

  • 10. Occurrence of ESBL & Amp-C beta-lactamases & susceptibility to newer antimicrobial agents in complicated UTI.
    Taneja N, Rao P, Arora J, Dogra A.
    Indian J Med Res; 2008 Jan 01; 127(1):85-8. PubMed ID: 18316858
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
    Ng TM, Khong WX, Harris PN, De PP, Chow A, Tambyah PA, Lye DC.
    PLoS One; 2016 Jan 01; 11(4):e0153696. PubMed ID: 27104951
    [Abstract] [Full Text] [Related]

  • 13. Ertapenem for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing bacteria in children.
    Dalgic N, Sancar M, Bayraktar B, Dincer E, Pelit S.
    Scand J Infect Dis; 2011 May 01; 43(5):339-43. PubMed ID: 21271945
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Risk factors for urinary tract infection caused by Enterobacteriaceae with extended-spectrum beta-lactamase resistance in patients admitted to internal medicine departments.
    Vardi M, Kochavi T, Denekamp Y, Bitterman H.
    Isr Med Assoc J; 2012 Feb 01; 14(2):115-8. PubMed ID: 22693794
    [Abstract] [Full Text] [Related]

  • 16. The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.
    Tamma PD, Rodriguez-Bano J.
    Clin Infect Dis; 2017 Apr 01; 64(7):972-980. PubMed ID: 28362938
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge.
    Rodríguez-Baño J, Navarro MD, Romero L, Muniain MA, de Cueto M, Ríos MJ, Hernández JR, Pascual A.
    Clin Infect Dis; 2006 Dec 01; 43(11):1407-14. PubMed ID: 17083012
    [Abstract] [Full Text] [Related]

  • 19. [Urinary Tract Infections Caused by Community-Acquired Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in a Level III Hospital - A Retrospective Study].
    Simões A, Lima M, Brett A, Queiroz C, Chaves C, Oliveira H, Januário L, Rodrigues F.
    Acta Med Port; 2020 Jul 01; 33(7-8):466-474. PubMed ID: 31962058
    [Abstract] [Full Text] [Related]

  • 20. Which proportion of extended-spectrum beta-lactamase producing strains could be treated by non-carbapenem beta-lactams?
    Canoui E, Tankovic J, Bige N, Alves M, Offenstadt G.
    Med Mal Infect; 2014 May 01; 44(5):235-7. PubMed ID: 24780641
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.